RT Journal Article
SR Electronic
T1 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
JF Cancer Biology & Medicine
JO Cancer Biology & Medicine
FD China Anti-Cancer Association
SP 129
OP 146
DO 10.20892/j.issn.2095-3941.2022.0585
VO 20
IS 2
A1 Li, Ping
A1 Liu, Yang
A1 Liang, Yun
A1 Bo, Jian
A1 Gao, Sujun
A1 Hu, Yongxian
A1 Hu, Yu
A1 Huang, He
A1 Huang, Xiaojun
A1 Jing, Hongmei
A1 Ke, Xiaoyan
A1 Li, Jianyong
A1 Li, Yuhua
A1 Liu, Qifa
A1 Lu, Peihua
A1 Mei, Heng
A1 Niu, Ting
A1 Song, Yongping
A1 Song, Yuqin
A1 Su, Liping
A1 Tu, Sanfang
A1 Wang, Jianxiang
A1 Wu, Depei
A1 Wang, Zhao
A1 Xu, Kailin
A1 Ying, Zhitao
A1 Yang, Qingming
A1 Zhang, Yajing
A1 Shi, Fengxia
A1 Zhang, Bin
A1 Zhang, Huilai
A1 Zhang, Xi
A1 Zhao, Mingfeng
A1 Zhao, Weili
A1 Zhao, Xiangyu
A1 Huang, Liang
A1 Zhu, Jun
A1 Qian, Wenbin
A1 Han, Weidong
A1 Liang, Aibin
YR 2023
UL http://www.cancerbiomed.org/content/20/2/129.abstract
AB Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.